

Bianca Saporiti
Regional Manager OVID Technologies

*The ovid technologies experience:
Accessing journals and books online
(Εμπορική Παρουσίαση)
(Commercial Presentation)*

Our Goal: _____

- Improve education
- Improve research
- Provide relevant, accurate, current content

Meeting Research Needs

- Life and health sciences researchers
- Students of healthcare, medicine, and hospital administration
- Professors

Ovid's Core Content

- All core biomedical databases
- Full text journals - Journals@Ovid
- Full text books - Books@Ovid
- Evidence-based medicine resources
- All linked together

Journals@Ovid -The Content

- 750+ premier titles available specific to health science
 - BMJ, NEJM, JAMA...
 - Top nursing titles
 - Many titles go back to 1993

ΠΕΜΠΤΗ 7 ΝΟΕΜΒΡΙΟΥ 2002

- PsycArticles -full text journals from APA
 - 43 premier full text psychology journals
- This year
 - All 750 Kluwer Academic Press titles
 - Plus 150 medical titles from Blackwell Publishers in 2002 - total to date 280 titles

journals@Ovid -The Features

- Title-by-title selection
- Access to table-of-contents and abstracts to all journals
- Fully 100% searchable
 - Cover-to-cover coverage
- PDF availability for printing
- Archive solution

Ovid's EBM Resources

- Leading provider of EBM resources
- Unique solution integrates EBM with more commonly used tools (MEDLINE)
 - EBM Reviews contains ACP Journal Club and the Cochrane Library- DARE, CCTR, and Cochrane Database of Systematic Reviews
 - All fully linked to both journals@Ovid and bibliographic databases
 - Online Ovid links from MEDLINE to EBM reviews based on studies reviewed

Books@Ovid

- 170+ premier clinical reference texts
 - OUP textbook titles
 - Author's such as Kaplan's, DeVita's, Greenfield's
 - Quick reference
 - Specialty texts, and nursing texts
- 100% searchable, 100% browsable


- 115 McGraw-Hill titles in total available by end of 2002 - many already loaded and live



Databases@Ovid



The most highly respected databases for medical research

- Including:
 - Medline and Pre-Medline (updated daily)
 - EBMR
 - C1NAHL
 - PsycINFO
 - BIOSIS
 - Current Contents
 - AMED (Allied and Complimentary Medicine)

Now let's see how it all integrates and works...







A screenshot of a Microsoft Internet Explorer browser window. The address bar shows the URL <http://www.onco.com/press/>. The page title is "Donepezil". The main content area displays "Search Results" with "Results 1 - 2 of 2 matches for donepezil". The first result is "100% Donepezil HCl" with a source of "Facts and Comparisons" and a link to http://www.onco.com/donepezil_hcl.htm. The second result is "99% Chapter 7. CENTRAL NERVOUS SYSTEM AGENTS" with a source of "Facts and Comparisons" and a link to http://www.onco.com/donepezil_hcl.htm. At the bottom, there are links for "Home", "New Search", and "Top".

A screenshot of a Microsoft Internet Explorer browser window showing the product page for Donepezil HCl. The address bar shows the URL <http://www.onco.com/press/>. The page title is "Donepezil HCl". The main content area displays "Donepezil HCl" and "Tablets, 5 and 10 mg (Rx) Aricept (Eisai/Pfizer)". Under "Indications:", it states "Alzheimer's disease: The treatment of mild-to-moderate dementia of the Alzheimer's type." Under "Administration and Dosage:", it states "The dosage of donepezil are 5 and 10 mg once per day in the evening, just prior to retiring." and "The higher dose of 10 mg did not provide a statistically significant clinical benefit greater than that of 5 mg. Do not increase to 10 mg until patients have been on a daily dose of 5 mg for 4 to 6 weeks." Under "Actions:", it states "Pharmacology: Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This increase in cholinergic function is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase (AChE). If this proposed mechanism of action is correct, donepezil's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that donepezil alters the course of the underlying dementing process." Under "Pharmacokinetics:", there is no text. The page also includes a small image of the product box and a sidebar with navigation links.

Back Forward Reload Home Search Help/Help/About Print Security Shop Help

http://gateway1.ovid.com/00/ovnews.cgi

WebMail Calendar Radio People Yellow Pages Download Customize

Choose a database

Select a database to search **select more than one database to search**

-- To begin a search, click the name of the desired database.
 -- To get more information about a database, click the information icon.
 -- Click the select more than one database to search tab to search up to 5 databases at once.
 -- Keyword

- MEDLINE 2002 to September Week 2 2003
- Medline@Ovid
- Clinique@Ovid
- Clinical Evidence Issue 7, August 2002
- MedCase@Ovid
- MedReviews
- Medline@Epub
- Lippincott's Clinical Consult
- Journals@Ovid Full Text November 25, 2002
- EBM@Ovid 1996 to September 23, 2002
- EBM Reviews - ACE Journal Club 1991 to July/August 2002
- EBM Reviews - Cochrane Controlled Trials Register 3rd Quarter 2002
- EBM Reviews - Cochrane Database of Systematic Reviews 3rd Quarter 2002
- EBM Reviews - Database of Abstracts of Reviews of Effects/Reviews 3rd Quarter 2002
- EBM Reviews Full Text - Cochrane DARE, ACE, Research Club, and DARE
- All EBM Reviews - Cochrane DARE, ACE, Journal Club, DARE, and CCTPR
- ACLA Reprints Database 1940 to January 2002
- AASH Archive 1976 to August 2002
- AERICOLA 1979 to September 2002
- AMU@Ovid 1974 to 2002 Week 30
- AMU@Ovid 1945 to 2002 Week 30

Book/Officed Microsoft Internet Explorer

http://www.ovid.com/00/ovnews.cgi

Medline

<1966 to May Week 3 2001>

Author Title Journal Year Tools Combine View Basic Search Logout

#	Search History	Results	Display

Enter Keyword or phrase: Alzheimer's disease

Map Term to Subject Heading

Limit to: Human English Language Review Articles Abstracts Latest Update

Ovid Full Text Available EBM Reports

Publication Year: -

Ask A Librarian

Copyright (c) 2000-2001 Ovid Technologies Inc.
 Version: rtk3.0, SourceID: 1 593 1 231

Bank's@Ovid - Microsoft Internet Explorer

http://pcv.ovid.com/pcv/

Mapping Display

Combine selections with: AND OR NOT WITH WITHOUT EXCEPT

Your term mapped to the following Subject Headings:
See term mapped to thesaurus term

Select	Subject Heading	Explode	Focus	Scope
<input checked="" type="checkbox"/>	Alzheimer Disease	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<input type="checkbox"/>	Alzheimer's disease mp. search as Keyword			

Hints:

- Check on a Subject Heading to view its tree - related terms that are more general and more specific.
- Select the Explode box if you wish to retrieve citations using the selected term and all of its more specific terms.
- Select the Focus box if you wish to limit your search to those documents in which your subject heading is considered the major point of the article.
- If your search did not map to a desirable subject heading, select the box Search as Keyword.
- If you select more than one term, you can combine them using a boolean operator (AND or OR).
- If you wish to see the scope note for any term or heading, click on the information icon, when available.

Copyright (c) 2000-2001 Ovid Technologies, Inc.
Version: 2443.0, SourceID: 1.5031.1251

Bank's@Ovid - Microsoft Internet Explorer

http://pcv.ovid.com/pcv/

Subheading Display

Combine selections with: AND OR NOT WITH WITHOUT EXCEPT

Subheadings for: Alzheimer Disease

Include All Subheadings (24491)
- or choose one or more of these subheadings -

<input type="checkbox"/> f1 - Blood (698)	<input type="checkbox"/> fmi - Microbiology (48)
<input type="checkbox"/> f2 - Cerebrospinal Fluid (600)	<input type="checkbox"/> fmo - Mortality (211)
<input type="checkbox"/> f3 - Chemically Induced (212)	<input type="checkbox"/> fmi - Nuring (627)
<input type="checkbox"/> f4 - Classification (337)	<input type="checkbox"/> fpi - Parasitology (2)
<input type="checkbox"/> f5 - Complications (1250)	<input type="checkbox"/> fpa - Pathology (5767)
<input type="checkbox"/> f6 - Diagnosis (4114)	<input type="checkbox"/> fpp - Physiopathology (3418)
<input type="checkbox"/> f7 - Diet Therapy (18)	<input type="checkbox"/> fpc - Prevention & Control (342)
<input type="checkbox"/> f8 - Drug Therapy (2447)	<input type="checkbox"/> fpm - Psychology (3953)
<input type="checkbox"/> f9 - Economics (204)	<input type="checkbox"/> fra - Radiography (222)
<input type="checkbox"/> f10 - Embryology (1)	<input type="checkbox"/> fri - Radionuclide Imaging (626)
<input type="checkbox"/> f11 - Enzymology (909)	<input type="checkbox"/> fth - Rehabilitation (133)
<input type="checkbox"/> f12 - Epidemiology (1222)	<input type="checkbox"/> fsu - Surgery (36)
<input type="checkbox"/> f13 - Etiology (110)	<input type="checkbox"/> fth - Therapy (1673)
<input type="checkbox"/> f14 - Etiology (1474)	<input type="checkbox"/> ftn - Transmission (22)
<input type="checkbox"/> f15 - Genetics (3579)	<input type="checkbox"/> fut - Ultrasonography (9)
<input type="checkbox"/> f16 - History (20)	<input type="checkbox"/> fu - Ulcer (15)

Back@Uoi - Microsoft Internet Explorer

http://acc.ovid.com/acc/

MEDLINE
 <1966 to May Week 3 2001>

Author Title Journal Search Tools Combine Links Basic Ovid Logout

#	Search History	Results	Display
1	Alzheimer Disease	24491	Display
2	limit 1 to (ovid full text available and ebn reviews)	15	Display

Enter Keyword or phrase: Map Term to Subject Heading

Limit to:
 Human English Language Review Articles Abstracts Latest Update
 Ovid Full Text Available EBM Reviews
 Publication Year: -

Ask a Librarian

Results of your search: **limit 1 to (ovid full text available and ebn reviews)**
 Citations displayed: 1-10 of 15
 Go to Record:

Back@Uoi - Microsoft Internet Explorer

http://acc.ovid.com/acc/

Results of your search: **limit 1 to (ovid full text available and ebn reviews)**
 Citations displayed: 1-10 of 15
 Go to Record:

1. Tariot PN, Solomon PR, Morris JC, Kerhaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-1 Study Group. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial] *Neurology*. 54(12):2269-76, 2000 Jun 27. UI 20342948
 Abstract • Complete Reference • Ovid Full Text • Topic Review • Library Holdings

2. Esakiand MA, Peskind ER, Westel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial] *Neurology*. 54(12):2261-9, 2000 Jun 27. UI 20342947
 Abstract • Complete Reference • Ovid Full Text • Topic Review • Library Holdings

3. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows ME, Sperling RA, Growdon JH. Donepezil therapy in clinical practice: a randomized crossover study [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial] *Archives of Neurology*. 57(1):94-9, 2000 Jan. UI 20097920
 Abstract • Complete Reference • Ovid Full Text • Topic Review • Library Holdings

4. Eosler M, Anand R, Cloin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman K, Gharebawi M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial [see comments] [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial] *BMJ*. 318(7180):633-8, 1999 Mar 6. UI 99165685
 Abstract • Complete Reference • Ovid Full Text • Article Review • Library Holdings

Book1@Dwid - Microsoft Internet Explorer

http://www.evid.com/revcof

The Cochrane Database of Systematic Reviews
The Cochrane Library, Copyright 2001, The Cochrane Collaboration

Volume (Issue 1) 2001 [no page #]

Donepezil for mild and moderate Alzheimer's disease
[Review]

Birks, JS, Meher, D, Beppo, E

Date of Most Recent Update: 30-8-2000
Date of Most Recent Substantive Update: 30-8-2000

Cochrane Dementia and Cognitive Improvement
Mrs Jacqueline Birks, Medical Statistician
University of Oxford, Department of Clinical Gerontology, Oxford, UK OX2 6HE
Phone: +44 1865 224031 Fax: +44 1865 224108 E-mail: jacqueline.birks@gerontology.ox.ac.uk

Search Use search buttons Filter criteria

Outline

- Abstract
- Background
- Objectives
- Comments for consideration: criteria for this review
 - Types of participants
 - Types of interventions

Outline...

Print Preview
Email Article Text

Links...

Book1@Dwid - Microsoft Internet Explorer

Book1@Dwid - Microsoft Internet Explorer

http://www.evid.com/revcof

10mg/day dose, except in the later study 211 when a four-week wash-in period was used. There were significantly more total drop-outs and drop-outs due to adverse events from the 10mg/day group than from the placebo or 5mg/day groups, and therefore side-effects remain a clinical issue.

Conclusions **Ⓜ**

Implications for practice **Ⓜ**

In selected patients with mild or moderate Alzheimer's disease treated for periods of 12, 24 and 52 weeks, donepezil at a dose of 10 mg/day produced modest improvements in cognitive function, measuring -2.9 points as a weighted mean (CI -3.6 to -2.2), in the mid-range of the 70 point ADAS-Cog Scale. Study clinician-rated global clinical state more positively in treated patients. However, no improvements were present on patients' self-assessed quality of life and data on many important outcomes are not available. Benefits on the 10mg/day dose were marginally larger than on the 5mg dose, although the higher dropout rate on the 10mg dose may have biased outcome measures.

The practical importance of these changes to patients and carers is unclear.

Subsequent to the trials there have been reports of psychological disturbance, agitation and aggressive behaviour in patients taking donepezil which resolved when the drug was withdrawn or the dose reduced (Drug and Therapeutics Bulletin 1998).

Implications for research **Ⓜ**

Trial evidence of the effects of donepezil when taken for more than one year are not available. Trials of longer duration, carried out on patients more representative of the general population of older people with Alzheimer's disease are required. The outcomes should include measures of dependency and effects on carers.

The adverse events reported in Drug and Therapeutics Bulletin (1998) did not occur in a trial situation and should be investigated further.

Intramural sources of support to the review **Ⓜ**



* Division of Clinical Gerontology, Nuffield Department of Clinical Medicine, University of Oxford UK

**

Extramural sources of support to the review **Ⓜ**

** NHS R & D UK

Book1@Dwid - Microsoft Internet Explorer



The screenshot shows a web browser window with a URL bar containing 'http://www.ovid.com/lookup/'. The main content area displays a study design diagram on the left and a text block on the right. The diagram is a flowchart showing the sequence of treatments: single-blind placebo wash-in, donepezil/hydrocortiside treatment and washout, and placebo treatment in random sequence. The text block, titled 'PATIENT EVALUATIONS:', describes the evaluation schedule (6, 12, 15, 18, 21, and 24 weeks) and the primary outcome measure, the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog).

Figure 1. Study design. Top, Crossover scheme of patients receiving single-blind placebo wash-in, followed by donepezil/hydrocortiside treatment and washout, and placebo treatment in random sequence. Primary outcome measure was the difference in Alzheimer's Disease Assessment Scale cognitive subscale scores at the beginning and end of each treatment period. Bottom, Flow diagram of patients enrolled in the study or who were withdrawn before or after randomization.

PATIENT EVALUATIONS:

Evaluations were performed at 6, 12, 15, 18, 21, and 24 weeks. This schedule ensured that patients randomized to either schedule would be tested at the beginning and end of their donepezil and placebo treatments, and after 3 weeks of drug washout. Evaluations included (1) cognitive testing and determination of caregiver-rated global impression (see following paragraph), (2) assessment of compliance with study medication use, and (3) interview with the caregiver to verify concurrent medication use and adverse events (including date of onset and cessation, severity, and temporal relation to administration of study medication). Cognitive testing was performed by a psychometrician who was masked to the patient's treatment status, adverse event profile, concomitant medication use, pill compliance, caregiver-rated global impression of change, and overall study design. A separate set of personnel (also masked to patient information) repeated the cognitive tests and entered data into a database.

The primary outcome measure was the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog), *19* an 11-item scale testing multiple areas of

The screenshot shows a web browser window displaying a list of references. The references are numbered 17 through 24. Reference 22 is circled in red. Below the references, there is a section for 'Accession Number: 00000916-20001000-00010' and a search bar with buttons for 'Search Results', 'Home', and 'Back to Top'. The footer of the page includes copyright information for 'Copyright (c) 2000-2001 Ovid Technologies, Inc.' and 'Version 0945.0, ServiceID: 15001.1.1.1'.

17. Blizard-G, Tomlinson BE, Folks M. The association between quantitative measures of dementia and of senile changes in the grey matter of elderly subjects. *Br J Psychiatry* 1986;149:797-811. [\[PubMed Link\]](#) [\[CrossRef Link\]](#)
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the clinician. *J Psychiatr Res* 1975;12:129-138. [\[PubMed Link\]](#) [\[CrossRef Link\]](#)
19. Rosen GW, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. *Am J Psychiatry* 1984;141:1256-1264. [\[PubMed Link\]](#) [\[CrossRef Link\]](#)
20. Randt CL, Brown ER, Osborne DP. A memory test for longitudinal measurement of mild to moderate deficits. *Clin Neuropsychol* 1980;2:184-194. [\[PubMed Link\]](#) [\[CrossRef Link\]](#)
21. Boscovitch JO, Benton AL, Spreen O. Word fluency and brain damage. *Neuropsychologia* 1967;5:123-149. [\[PubMed Link\]](#)
22. Quinlan H, O'Keefe A, Higgins J, Wilcock G, Johnston L, Fallow M. Cholinesterase inhibitors for Alzheimer disease: a meta-analysis of the tacrine trials. *JAMA* 1998;280:1777-1783. [\[PubMed Link\]](#) [\[CrossRef Link\]](#) [\[CrossRef Link\]](#) [\[CrossRef Link\]](#) [\[CrossRef Link\]](#) [\[CrossRef Link\]](#)
23. Quinlan T, West HL, Roberts CW, et al. Clinical and pathological correlates of apolipoprotein E epsilon4 in Alzheimer's disease. *Ann Neurol* 1996;39:62-70. [PubMed Link\]](#) [\[CrossRef Link\]](#) [\[CrossRef Link\]](#)
24. Conroy EL. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease, methodologic considerations. *Clin Neuropharmacol* 1998;21:3-17. [PubMed Link\]](#) [\[CrossRef Link\]](#) [\[CrossRef Link\]](#) [\[CrossRef Link\]](#) [\[CrossRef Link\]](#)

Not Available

Accession Number: 00000916-20001000-00010

Search Results Home Back to Top

Copyright (c) 2000-2001 Ovid Technologies, Inc.
Version 0945.0, ServiceID: 15001.1.1.1

JAMA
The Journal of the American Medical Association

Copyright, 1998 by the American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
 American Medical Association, 515 N. Dear St, Chicago, IL 60610.

Volume 280(26) 25 November 1998 pp 1777-1782

Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials
 (Review)

Qizilbash, Nawab MRCP, DPhil, Whitehead, Anne MSc, Higgins, Julian, PhD, Witcock, Gordon FRCP, DM, Schneider, Lon MD, Fallow, Martin MD

The Dementia Trials' Collaboration. From the Dementia Trials' Collaboration, Cochrane Dementia Group, Department of Clinical Gerontology, University of Oxford, Radcliffe Infirmary, Oxford, England (Dr Qizilbash); MPR Research Unit, University of Reading, England (Ms Whitehead); Systematic Reviews Training Unit, Institute of Child Health, London, England (Dr Higgins); Department of Care of the Elderly, Frenchay Hospital, Bristol, England (Dr Witcock); Department of Psychiatry, University of Southern California School of Medicine, Los Angeles (Dr Schneider); and Department of Neurology, Indiana University School of Medicine, Indianapolis (Dr Fallow).

Outline

- Abstract
- METHODS
 - Identification of Studies and Collection of Data
 - Statistical Analysis
- RESULTS
 - Synthesis
 - Clinical Global Impression of Change
 - References

Output...

- Print preview
- Email article text
- Save article text

Links...

- About this Journal
- Help

Ovid Databases

The Resources, Tools and Services...

energize your thinking™

Full Text Journals, Reference Books, Databases

...For the Best Search Results Every Time

Let the advantages of Ovid work for you in your education and research